Internal Medicine, Rheumatology · Dover, DE
NPI
1689024143
Since 2016
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1100 Forrest Ave
Dover, DE, 19904
Phone (302) 674-4627
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.8M
180,843 services
Medicare patients, 2024
466
Average age 74
Drug cost, 2024
$1.2M
1,375 prescriptions
Company payments, 2025
$2,822
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Surjeet S Dheer was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 75,200 times for 20 patients. In total Surjeet S Dheer billed 180,843 services in 48 codes, and Medicare paid $1.8M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-22.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 75,200 | 20 | $3.62 | $272K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 25,830 | 25 | $8.55 | $221K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 18,450 | 21 | $9.12 | $168K |
| J0897 Injection, denosumab, 1 mg | Office | 14,460 | 157 | $20.38 | $295K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 9,150 | 16 | $33.85 | $310K |
| 99214 Office E&M - Established | Office | 646 | 363 | $90.53 | $58K |
| 96401 Chemotherapy Administration | Office | 608 | 46 | $52.10 | $32K |
| 96372 Injection Administration | Office | 275 | 173 | $10.01 | $2,752 |
| 96413 Chemotherapy Administration | Office | 236 | 41 | $95.43 | $23K |
| 96365 Intravenous Infusion, Hydration | Office | 154 | 45 | $44.97 | $6,926 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 123 | 25 | $4.65 | $573 |
| 99204 Office E&M - New | Office | 73 | 73 | $114.06 | $8,326 |
| 99442 Telephone Services | Office | 70 | 62 | $63.35 | $4,434 |
| 96415 Chemotherapy Administration | Office | 61 | 12 | $20.24 | $1,235 |
| 99213 Office E&M - Established | Office | 52 | 50 | $63.56 | $3,305 |
By year: 2022 $165K for 3,606 services; 2023 $1.2M for 76,297 services; 2024 $1.8M for 180,843 services.
Medicare prescription drug claims, 2024
In 2024, the drug Surjeet S Dheer prescribed most often to Medicare patients was Prednisone, with 206 prescriptions and refills. In total Surjeet S Dheer wrote 1,375 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 206 | 375 | 77 | $1,543 |
| Hydroxychloroquine Sulfate Generic | 149 | 416 | 50 | $10K |
| Methotrexate Methotrexate Sodium | 135 | 352 | 40 | $5,225 |
| Celecoxib Generic | 99 | 285 | 43 | $4,449 |
| Meloxicam Generic | 98 | 283 | 44 | $763 |
| Tramadol Hcl Generic | 54 | 56 | 16 | $321 |
| Allopurinol Generic | 50 | 150 | 16 | $674 |
| Leflunomide Generic | 42 | 114 | 15 | $4,068 |
| Diclofenac Sodium Generic | 40 | 93 | 19 | $970 |
| Tymlos Abaloparatide | 36 | 54 | Under 11 | $140K |
| Methylprednisolone Generic | 35 | 49 | 24 | $691 |
| Gabapentin Generic | 32 | 90 | 11 | $855 |
| Pregabalin Generic | 23 | 65 | Under 11 | $575 |
| Duloxetine Hcl Generic | 22 | 65 | Under 11 | $678 |
| Folic Acid Generic | 21 | 64 | Under 11 | $231 |
Brand drugs: - claims; generic drugs: 1,199 claims; opioid claims: 72.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Surjeet S Dheer $2,822 ($2,822 in general payments such as food, travel and fees) from 17 companies. The largest payer was Abbvie Inc. with $801.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 38 | $801 |
| UCB, Inc. UCB.BR | 24 | $489 |
| Janssen Biotech, Inc. JNJ | 16 | $370 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $262 |
| Amgen Inc. AMGN | 13 | $201 |
| GlaxoSmithKline, LLC. GSK | 4 | $84.76 |
| Eisai Inc. 4523.T | 1 | $82.8 |
| AstraZeneca Pharmaceuticals LP AZN | 4 | $77.43 |
| Lilly USA, LLC LLY | 3 | $75.87 |
| Pfizer Inc. PFE | 4 | $74.53 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.